Lexaria Bioscience has partnered with a world-leading tobacco company to license their technology.
Lexaria Bioscience Corp. acquired the precursor to the DehydraTECH™ technology in 2014 and has since strengthened and broadened the technology to an unprecedented degree. Lexaria has emerged as a global leader in enhancing the speed of action, flavor and gastro-intestinal delivery of orally-administered products.The Lexaria family of companies has also demonstrated early-stage effectiveness in improvements of delivery through human skin for the potential development of topically-administered products, including patches, cremes and lotions.In 2018, Lexaria created four different wholly-owned subsidiary companies to each focus on commercial opportunities in their respective industries: Nicotine; Pharmaceuticals; Hemp; and Other. Together, they are empowered with global exclusive licenses to utilize and sub-license DehydraTECH worldwide for the delivery of molecules within their respective industries.Lexaria has conducted ground-breaking studies to open doors previously closed to disruptive new delivery technology, including the possibility of potent and fast acting ingestible products that avoid the lung diseases and cancers caused by inhalation of combusted molecules common in smoking. And, because of the demonstrated improvements in delivery, DehydraTECH also opens the possibility of utilizing micro doses in accordance with evolving FDA policies related to reducing delivered quantities of substances like nicotine.In 2018, Lexaria demonstrated in animal studies a propensity for the DehydraTECH technology to elevate the quantity of drug delivered across the blood-brain-barrier, initiating additional new patent applications.Lexaria produces industry-leading research to support its novel delivery methods. Lexaria’s business model depends on industry partners who license its technology for additional R&D and consumer product development.For more information on Lexaria Biosciences Corp. (LXX:CSE, LXRP:OTCQX) please fill out the form below.